This symposium delves into the pivotal role of type 2 inflammation in diverse skin conditions, including atopic dermatitis, prurigo nodularis, chronic spontaneous urticaria, and bullous pemphigoid. It highlights both shared and distinct disease mechanisms and patient burdens, providing crucial insights for optimizing clinical management strategies through a series of engaging panel discussions with Drs Eichenfield, Elmariah, Culton, and Hawkes.

This interactive tool systematically guides healthcare providers through the complete diagnostic pathway for suspected bullous pemphigoid and provides a comparative overview of leading international treatment guidelines to inform optimal patient management.

Dr. Amy Paller discusses the clinical utility of TARC measurements in AD management at EADV 2025
Dr Lawrence Eichenfield explores the broadening of treatment goals for long-term disease control, highlighting the importance of this approach in atopic dermatitis. Drs Culton, Elmariah, and Hawkes expand the discussion to further examine specific management goals unique to each skin disease (bullous pemphigoid, prurigo nodularis, and chronic spontaneous urticaria).
Join Professors Klaus Rabe and Ian Pavord as they discuss the importance of on-treatment clinical remission as a goal in asthma management.
Use this educational tool to explore the daily burden of loss of smell for patients with CRSwNP.
Join Dr. Sarina Elmariah as she discusses the challenges in diagnosing prurigo nodularis.

Many AD treatment goals focus on clinical manifestations, so that if a patient is free of lesions, their disease is considered well controlled. However, the inflammatory process underlying AD reaches far beyond the skin, affecting patients in unique ways at different stages of their lives. Education on the importance of treating AD beyond the skin and altering the treatment approach to fit the individual patient will help improve clinical management and reduce long-term patient burden.

This infographic illustrates the ongoing burden associated with maintenance oral corticosteroid (OCS) use and high-dose inhaled corticosteroids (ICS) in asthma, including the clinical impact of corticosteroid exposure, supporting evidence, and the importance of considering corticosteroid burden in asthma management.
Experience this engaging presentation by Dr. Donna Culton, Prof. Dédée Murrell, and Prof. Ulrike Raap, who highlight the heterogeneous clinical presentations of BP and its burden, delve beneath the surface into how autoimmunity and predominantly type 2 inflammation mediate the disease, and explore the evolving toolbox of current approaches in BP management.

Dr Jason Hawkes describes the importance of early intervention for patients with uncontrolled skin diseases and the effectiveness of evidence-based management strategies, sharing a patient case and his clinical insights with chronic spontaneous urticaria. Drs Eichenfield, Elmariah, and Culton join to review the burdens faced by patients with atopic dermatitis, prurigo nodularis, and bullous pemphigoid, respectively.

Join experts G. Walter Canonica, Vibeke Backer, and Joaquim Mullol for an educational symposium on elevating treatment goals from control to remission in the upper and lower airways.